TIBOTEC PHARMACEUTICALS LTD RETURNS MIV-210 LICENSING RIGHTS TO MEDIVIR

Medivir has today announced that the licensing rights for MIV-210 have reverted to Medivir from Tibotec Pharmaceuticals Ltd.

In previously performed pre-clinical trials, MIV-210 has demonstrated very potent activity against Hepatitis B Virus (HBV) and has good pharmacokinetic properties.

MIV-210 belongs to the class of polymerase inhibitors being administered by subsidiary Medivir HIV Franchise AB.



For additional information, please contact
Rein Piir, CFO & VP Investor Relations, Medivir AB +46 8 5468 3123
or +46 708 537 292

For further information about Medivir, please see our website: www.medivir.se